Urothelial Cancer | Specialty

The OncLive Urology condition center page is a comprehensive resource for clinical news and expert insights on urologic cancers, including prostate cancer, bladder cancer, testicular cancer, penile cancer, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

N-803 Plus BCG Generates Strong, Durable Response in Non–Muscle Invasive Bladder Cancer

January 4th 2023

N-803, a novel IL-15 superagonist, in combination with intravesical Bacillus Calmette–Guérin induced an overall response in more than two-thirds of patients with non–muscle invasive bladder cancer.

FDA Accepts sBLAs for Enfortumab Vedotin/Pembrolizumab in Advanced Urothelial Cancer

December 20th 2022

The FDA has granted a priority review to a supplemental biologics license applications for enfortumab vedotin and pembrolizumab used in combination for the treatment of patients with locally advanced or metastatic urothelial cancer who are not eligible to receive cisplatin-containing chemotherapy.

FDA Approves Nadofaragene Firadenovec for High-risk Non–Muscle Invasive Bladder Cancer

December 16th 2022

The FDA has approved nadofaragene firadenovec-vncg (Adstiladrin) for the treatment of adult patients with high-risk Bacillus Calmette-Guérin–unresponsive non–muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors.

Budigalimab Plus ABBV-151 Demonstrates Variable Activity Across Locally Advanced or Metastatic Solid Tumors

December 6th 2022

The addition of budigalimab to ABBV-151 was well tolerated and significantly enhanced responses in patients with locally advanced or metastatic solid tumors.

Dr. Schmid on Next Steps for the RACE IT Trial in Urothelial Carcinoma

December 1st 2022

Sebastian C. Schmid, MD, discusses the future of the phase 2 RACE IT trial in urothelial carcinoma.

CG0070/Pembrolizumab Combo Shows Promising Efficacy and Tolerability in NMIBC

November 30th 2022

The oncolytic vaccine CG0070 plus pembrolizumab demonstrated encouraging response rates and a tolerable safety profile in patients with non–muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guérin.

Roche to Withdraw US Indication for Atezolizumab in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma

November 29th 2022

Roche is voluntarily withdrawing the United States indication for atezolizumab for the treatment of adults with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy.

Dr. Schmid on the Rationale for the RACE IT Trial in Advanced Urothelial Carcinoma

November 15th 2022

Sebastian C. Schmid, MD, discusses the rationale for the phase 2 RACE IT trial in urothelial carcinoma.

Dr. Gupta on the Investigation of Enfortumab Vedotin With or Without Additional Therapy in mUC

November 14th 2022

Shilpa Gupta, MD, discusses the investigation of enfortumab vedotin with or without additional therapy in cisplatin-ineligible metastatic urothelial carcinoma.

Dr. Siefker-Radtke on Unmet Needs in Frontline Urothelial Cancer Treatment

November 14th 2022

Arlene O. Siefker-Radtke, MD, discusses key therapeutic developments aimed at addressing unmet needs in metastatic urothelial carcinoma treatment.

Dr. Siefker-Radtke on Erdafitinib in Urothelial Carcinoma

November 11th 2022

Arlene O. Siefker-Radtke, MD, discusses the use of erdafitinib in urothelial carcinoma.

Petrylak Previews Shift in Sequencing Paradigm in Urothelial Cancer

November 9th 2022

Daniel P. Petrylak, MD, highlights the use of checkpoint inhibitors, antibody-drug conjugates, and FGFR inhibitors in urothelial cancer and the current sequencing hurdles in the paradigm.

Dr. Gupta on Unmet Needs in Frontline Treatment of Metastatic Urothelial Cancer.

November 4th 2022

Shilpa Gupta, MD, discusses the unmet needs of patients with cisplatin-ineligible metastatic urothelial carcinoma.

Dr. Sonpavde on the Investigation of Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

October 31st 2022

Guru P. Sonpavde, MD, discusses the investigation of enfortumab vedotin-ejfv with or without pembrolizumab in urothelial cancer.

Key Trial Data in Urothelial Carcinoma Treatment from ESMO 2022

October 26th 2022

Srikala Sridhar, MD, MSc, FRCPC, and Jeanny B. Aragon-Ching, MD, FACP, wrap up their review of updates in urothelial carcinoma by highlighting exciting data presented at ESMO 2022.

Metastatic Urothelial Carcinoma Treatment after Disease Progression on Avelumab

October 26th 2022

Key opinion leaders discuss the best treatment approaches for urothelial carcinoma after avelumab failure.

Dr. Aragon-Ching on the Future Implications of the JAVELIN Bladder 100 Trial in Urothelial Cancer

October 24th 2022

Jeanny B. Aragon-Ching, MD, FACP, discusses the future implications of the phase 3 JAVELIN Bladder 100 trial in urothelial cancer.

Mitomycin C Reduces the Number of Procedures Following NMIBC Recurrence

October 21st 2022

Chemoresection with mitomycin C, a nonsurgical treatment modality, significantly reduced the need for transurethral resection of bladder tumors or office biopsy and tumor fulguration following recurrence in patients with recurrent nonmuscle invasive bladder cancer.

Rogaratinib Is Noninferior to Chemo in Pretreated FGFR1/3 mRNA+ Locally Advanced or Metastatic Urothelial Carcinoma

October 19th 2022

Rogaratinib induced an objective response rate similar to that of chemotherapy in patients with FGFR1/3 mRNA–positive locally advanced or metastatic urothelial carcinoma who have received at least 1 prior platinum-containing chemotherapy.

Outcomes of the JAVELIN Bladder 100 Trial

October 19th 2022

Jeanny B. Aragon-Ching, MD, FACP, describes the outcomes of the JAVELIN Bladder 100 study that she presented at ESMO 2022.